A 68-year-old Indian man with a 10-year history of smoking presents with gradual painless central vision loss over the past 18 months. Fundus examination reveals large drusen (>125 μm), retinal pigment epithelium (RPE) atrophy with a sharply demarcated pale patch, and visible choroidal vessels through the atrophic zone. The foveal center marked **D** in the diagram remains relatively spared at present. Which of the following best describes the natural history and prognosis of this patient's condition?

Explanation

## Why Geographic atrophy (dry AMD) with gradual central vision loss over years; foveal sparing initially common but eventual foveal involvement leads to legal blindness if untreated is right The clinical presentation—large drusen (>125 μm), RPE atrophy with sharp-edged pale patch, visible choroidal vessels, and gradual painless central vision loss—is pathognomonic for late dry (atrophic, non-exudative) AMD with geographic atrophy (GA). The foveal center marked **D** is initially spared in many cases of GA, but this sparing is temporary; progressive RPE and photoreceptor loss eventually involves the fovea, resulting in severe central vision loss and legal blindness if untreated. Dry AMD accounts for ~80% of AMD cases and progresses over years, unlike wet AMD which is sudden. Per Khurana Ophthalmology 7e, GA is characterized by sharply demarcated areas of RPE loss with visible choroidal vessels—exactly what this patient demonstrates. The smoking history (single strongest modifiable risk factor, 2–4× risk) accelerates progression. ## Why each distractor is wrong - **Wet AMD with choroidal neovascularization; sudden metamorphopsia and central scotoma expected within weeks; accounts for ~90% of AMD-related legal blindness**: While wet AMD does account for ~90% of legal blindness historically, this patient's presentation is dry AMD with GA, not wet AMD. Wet AMD presents with SUDDEN distortion (metamorphopsia) and rapid vision loss, not gradual painless loss over 18 months. The absence of subretinal/intraretinal fluid or hemorrhage on clinical description rules out CNV. - **Intermediate AMD with small drusen and no pigment changes; excellent prognosis with lifestyle modification alone; AREDS2 supplementation not indicated**: This patient has LARGE drusen (>125 μm) with RPE pigment changes and atrophy—criteria for late AMD, not intermediate AMD. Intermediate AMD has drusen 63–125 μm and may have pigment changes but no atrophy. AREDS2 is indicated for intermediate AMD or unilateral late AMD to reduce 5-year progression by ~25%. - **Early AMD with drusen <125 μm; minimal risk of progression to late AMD; annual monitoring sufficient without intervention**: Early AMD is defined by small/medium drusen (<125 μm) without pigment changes. This patient has large drusen (>125 μm), RPE atrophy, and geographic atrophy—all late AMD features. Early AMD has much lower progression risk; late AMD requires closer monitoring and intervention. **High-Yield:** Geographic atrophy (dry AMD) = gradual, painless, foveal sparing initially but eventual foveal involvement; wet AMD = sudden, distortion, rapid; smoking accelerates both; AREDS2 for intermediate AMD or unilateral late AMD. [cite: AK Khurana Ophthalmology 7e Ch 16]